Claro Advisors LLC Buys 222 Shares of Amgen Inc. (NASDAQ:AMGN)

Claro Advisors LLC boosted its stake in Amgen Inc. (NASDAQ:AMGN) by 4.7% during the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 4,912 shares of the medical research company’s stock after purchasing an additional 222 shares during the quarter. Claro Advisors LLC’s holdings in Amgen were worth $1,583,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Capital Performance Advisors LLP bought a new position in Amgen during the third quarter valued at approximately $25,000. Hershey Financial Advisers LLC purchased a new position in shares of Amgen in the second quarter valued at $30,000. nVerses Capital LLC purchased a new stake in Amgen during the second quarter valued at $31,000. Bbjs Financial Advisors LLC bought a new position in Amgen during the second quarter valued at $33,000. Finally, Matrix Trust Co purchased a new position in shares of Amgen in the 3rd quarter worth $36,000. Institutional investors own 76.50% of the company’s stock.

Analyst Upgrades and Downgrades

AMGN has been the subject of several recent research reports. Deutsche Bank Aktiengesellschaft reiterated a “hold” rating and issued a $305.00 price target (down previously from $310.00) on shares of Amgen in a research report on Wednesday, August 7th. UBS Group decreased their price target on Amgen from $335.00 to $326.00 and set a “neutral” rating on the stock in a report on Thursday, October 31st. Robert W. Baird reiterated an “underperform” rating and set a $215.00 price objective on shares of Amgen in a research report on Wednesday, September 25th. Dbs Bank upgraded shares of Amgen to a “strong-buy” rating in a report on Monday, September 16th. Finally, Oppenheimer reiterated an “outperform” rating and set a $380.00 price target on shares of Amgen in a report on Wednesday, August 7th. One equities research analyst has rated the stock with a sell rating, thirteen have given a hold rating, eleven have assigned a buy rating and two have given a strong buy rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $333.57.

Amgen Trading Down 4.2 %

AMGN opened at $283.61 on Friday. Amgen Inc. has a 12 month low of $260.52 and a 12 month high of $346.85. The stock has a fifty day moving average price of $320.85 and a 200-day moving average price of $318.36. The firm has a market cap of $152.45 billion, a price-to-earnings ratio of 36.31, a PEG ratio of 2.53 and a beta of 0.60. The company has a current ratio of 1.32, a quick ratio of 0.96 and a debt-to-equity ratio of 7.55.

Amgen (NASDAQ:AMGN) last released its quarterly earnings results on Wednesday, October 30th. The medical research company reported $5.58 earnings per share for the quarter, beating analysts’ consensus estimates of $5.11 by $0.47. The business had revenue of $8.50 billion for the quarter, compared to analysts’ expectations of $8.50 billion. Amgen had a net margin of 13.00% and a return on equity of 168.35%. The company’s revenue was up 23.2% compared to the same quarter last year. During the same period last year, the business earned $4.96 EPS. As a group, equities research analysts anticipate that Amgen Inc. will post 19.51 earnings per share for the current fiscal year.

Amgen Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, December 9th. Stockholders of record on Monday, November 18th will be issued a dividend of $2.25 per share. The ex-dividend date is Monday, November 18th. This represents a $9.00 annualized dividend and a dividend yield of 3.17%. Amgen’s dividend payout ratio is presently 115.24%.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.